Valeant announces pricing for Siliq for plaque psoriasis

Valeant Pharmaceuticals International announced that the company will list Siliq injection at $3,500 per month for patients with moderate-to-severe plaque psoriasis.

The FDA approved Siliq (brodalumab) injection as treatment for moderate-to-severe plaque psoriasis in February. The monoclonal antibody targets the IL-17 receptor, and is indicated for patients who are candidates for systemic therapy or phototherapy and have failed to response or lost response to other systemic therapies, according to a press release from Valeant.

The pricing was determined following evaluation and approval of Valeant’s Patient Access and Pricing Committee (PAPC). It will be the lowest priced injectable biological psoriasis treatment currently on the market and will be including in Valeant’s patient access program to offer further financial support to patients, according to a press release.

Siliq includes a Black Box Warning for risk of patients with a history of suicidal thoughts or behavior, and was approved with a Risk Management and Mitigation Strategy involving a one-time enrollment for physicians and a one-time informed consent for patients, according to the release. Suicidal ideation and behavior have been reported with Siliq, according to Valeant.

Common adverse events include headache, arthralgia, fatigue, oropharyngeal pain and diarrhea, according to the release.

Valeant reports that sales are expected to begin during the second half of 2017 in the U.S.

Reference: www.valeant.com